New Indications, Mechanisms Drive Second-Line Treatments
Source: Dermatology Times, January 2022
Patients suffering from a wide range of dermatologic diseases can benefit from the new and exciting therapies and treatment modalities that have recently become available.
Patients with moderate to severe atopic dermatitis (AD) have seen the pipeline continue to expand and that trend remains strong. Continued research has led to the development of new treatment options for patients with the skin disease such as the monoclonal antibody dupilumab (Dupixent, Sanofi/Regeneron Pharmaceuticals, Inc), which has been shown to have significantly improved outcomes in patients.
The dawn of novel JAK inhibitors such as upadacitinib (Rinvoq; Abbvie) for severe AD may possibly be even more effective than dupilumab, giving this patient population yet another safe and effective treatment option to help them clear their moderate to severe disease.